SAGE's Cookie Policy
Close 

To enhance your experience on our site, SAGE stores cookies on your computer. By continuing you consent to receive cookies.

Learn More

Therapeutic Advances in Respiratory Disease

Editor-in-Chief:
University General Hospital Vall d'Hebron, Barcelona, Spain
Editor:
SAGE Publications Ltd, London, UK
Associate Editors:
University of Texas, San Antonio, TX, USA
St Paul’s Hospital, Vancouver, BC, Canada
Medizinische Hochschule, Hannover, Germany
Southampton General Hospital, Southampton, UK
 

Therapeutic Advances in Respiratory Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of respiratory disease.
 
The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in respiratory disease, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of respiratory disease, including emerging therapies for chronic obstructive pulmonary disease, asthma, pulmonary hypertension and the exacerbations caused by infections and smoking.

It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online.

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

Commercial Sales Team, London, UK
Tel. +44 20 7336 1205
Email. reprints@sagepub.co.uk

This journal is a member of the Committee on Publication Ethics (COPE)

Subscription Information :
Institutional Subscription, Combined (Print & E-access) £638.00
Institutional Subscription, E-access £574.00
Institutional Subscription, Print Only £625.00
Individual Subscription, Print Only £82.00

To purchase a non-standard subscription or a back issue, please contact SAGE Customer Services for availability.
subscriptions@sagepub.co.uk +44 (0) 20 7324 8701

Institutional, Single Print Issue £115.00
Individual Single Print Issue £18.00
Frequency: Published 6 times a year eISSN: 1753-4666 ISSN: 1753-4658
Months of Distribution: February , April , June , August , October , December Current Volume: 8 Current Issue: 2
Other Titles in: Pulmonary & Respiratory Medicine  |  Chronic Obstructive Pulmonary Disease (COPD)  |  Therapeutic Approaches

Product Type

All

Subject Areas

All